openPR Logo
Press release

Rare Disease Market is estimated to be US$ 547.5 billion by 2030 with a CAGR of 13.1% during the forecast period With Top Most Key Players - Hoffmann-La Roche, Abbott, Pfizer, Sanofi, Eli Lilly, Genelux, Mercks & co., Glaxosmith Kline, Astra Zeneca, Eisai

11-09-2022 12:47 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Prophecy Market Insights

Rare Disease Market is estimated to be US$ 547.5 billion by 2030

Rare Disease Market accounted for US$ 161.4 billion in 2020 and is estimated to be US$ 547.5 billion by 2030 and is anticipated to register a CAGR of 13.1%. Rare disease is any disease that affects a small percentage of the total population. In some parts of the world, an orphan disease is a rare disease whose rarity supports that there is a lack of a market large enough to gain support and resources for discovering treatments for it, except by the government granting economically advantageous conditions for creating and selling such treatments. Orphan drugs are ones in thousand so these drugs are created and sold boosting the market.

To know the upcoming trends and insights prevalent in this market, click the link below:
https://www.prophecymarketinsights.com/market_insight/global-rare-disease-market-4634

The report " Global Rare disease Market, By Drug Type (Biologics and Non-biologics),By Route of Administration (Oral and Injectable), By Phase (Preclinical, Phase1, Phase2, Phase3 and Phase4), By Therapeutic Area (Infectious disease, Neurological, Alimentary/Metabolic, Cancer, Blood & Clotting and Others), By Patients (Neonatal, Pediatric, Adult), By Distribution Channel (Hospital & Retail Pharmacies, e-Commerce/Online Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030"

Key Highlights:
• The National Institute of Health (NIH) and Food and Drug Administration (FDA) regulate the training and guidance to improve the quality and marketing of NIH-funded rare diseases drugs. Additionally, NIH has also initiated several programs to support drug delivery for rare diseases.
• According to a COVID-19 Community Survey report by the National Organization for Rare Disorders (NORD), around 74% patients are suffering from rare disorders in the U.S. face challenges in accessing high-quality medication

Analyst View:
According to the European Organization for Rare Diseases (EURORDIS) estimates, approximately, 6% to 8% of the population in European Union is affected by a rare disorder. Therefore, several research laboratories are focusing on R&D to fulfill the demand for specific therapeutics for the treatment of rare disorders such as rare cardiovascular disorders and fatal familial insomnia. As awareness among patients and development of new technologies are rapidly increasing meanwhile it boost the market further. Furthermore, detection of rare disease with their treatment might drive the global rare disease market.
Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on "Global Rare disease Market, By Drug Type (Biologics and Non-biologics),By Route of Administration (Oral and Injectable), By Phase (Preclinical, Phase1, Phase2, Phase3, Phase4), By Therapeutic Area (Infectious disease, Neurological, Alimentary/Metabolic, Cancer, Blood & Clotting and Others), By Patients (Neonatal, Pediatric, Adult), By Distribution Channel (Hospital & Retail Pharmacies, e-Commerce/Online Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030"

Click To Get Sample Report:-
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4634

Segments Covered in the Report:

Rare disease Market,By Drug Type:
• Biologics
• Non-biologics

Rare disease Market,By Route of Administration:
• Oral
• Injectable

Key Market Insights from the report:
Global Rare Disease Market accounted for US$ 161.4 billion in 2020 and is estimated to be US$ 547.5 billion by 2030 and is anticipated to register a CAGR of 13.1%. Global Rare Disease Market is segmented based on the drug type, route of administration, phase, therapeutic area, patients, distribution channel, and region.
• By Drug type, the global rare disease market is segmented into Biologics and Non-Biologics.
• By Route of Administration, the global rare disease market is segmented into Oral and Injectable.
• By Phase, the global rare disease market is segmented into Preclinical, Phase1, Phase2, Phase3, Phase4.
• By Therapeutic Area, the global rare disease market is segmented into Infectious disease, Neurological, Alimentary/Metabolic, Cancer, Blood & Clotting and Others.
• By Therapeutic Area, the global rare disease market is segmented into Infectious disease, Neurological, Alimentary/Metabolic, Cancer, Blood & Clotting and Others.
• By Patients, the market is segmented in Neonatal, Pediatric, Adults.
• By Distribution Channel, the global rare disease market is segmented into Hospital & Retail Pharmacies, and E-commerce/Online Pharmacies.
• By region, the global rare disease market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the worldwide leader in the rare disease market in terms of revenue, due to the developed healthcare system and health awareness among people.

Competitive Landscape:
The key players operating in the global rare disease market include Hoffmann-La Roche, Abbott, Pfizer, Sanofi, Eli Lilly, Genelux, Mercks & co., Glaxosmith Kline, Astra Zeneca, Eisai, Rexahn and Taino.
The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

Other Related Reports:-

https://www.prophecymarketinsights.com/market_insight/-Dashboard-Camera-Market-By-2210

https://www.prophecymarketinsights.com/market_insight/Global-Internet-of-Things-IOT-250

https://www.prophecymarketinsights.com/market_insight/-Transformer-Oil-Market-By-2406

964 E. BadilloStreet #2042 Covina, CA 91724
US toll free: +1 860 531 2701
Rest of world: + 91 7775049802
Email:sales@prophecymarketinsights.com
Website:www.prophecymarketinsights.com

About us:Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rare Disease Market is estimated to be US$ 547.5 billion by 2030 with a CAGR of 13.1% during the forecast period With Top Most Key Players - Hoffmann-La Roche, Abbott, Pfizer, Sanofi, Eli Lilly, Genelux, Mercks & co., Glaxosmith Kline, Astra Zeneca, Eisai here

News-ID: 2799310 • Views:

More Releases from Prophecy Market Insights

Indoor Air Quality Market: Breathing Life into Healthy Living and Sustainable Workspaces
Indoor Air Quality Market: Breathing Life into Healthy Living and Sustainable Wo …
Author: Shweta R., Business Development Specialist, Prophecy Market Insights Introduction The quality of the air we breathe has become a critical public health concern and a business priority worldwide. As urbanization intensifies, populations grow, and workplaces become increasingly technology-driven, the demand for Indoor Air Quality (IAQ) solutions is on the rise. From homes and offices to hospitals, educational institutions, and industrial facilities, ensuring clean indoor air is no longer optional-it is a
[PDF] Surface Analysis Market: Unlocking Precision in Material Science and Industrial Innovation
[PDF] Surface Analysis Market: Unlocking Precision in Material Science and Indus …
Author: Shweta R., Business Development Specialist Introduction The Surface Analysis Market is transforming the way industries understand, optimize, and innovate across materials and products. From semiconductors and aerospace to healthcare and nanotechnology, surface analysis techniques provide unmatched insights into composition, structure, and properties at the micro and nano scale. In today's innovation-driven economy, surface analysis has become more than a laboratory technique-it's a strategic enabler for product performance, quality assurance, and sustainability. As
Bio-based Composite Material Market Outlook 2035: Size, Growth, Key Players, and Future Trends
Bio-based Composite Material Market Outlook 2035: Size, Growth, Key Players, and …
Bio-based composite materials are innovative materials made by combining natural fibers, resins, and bio-polymers derived from renewable sources. These composites are lightweight, durable, and environmentally sustainable, making them a preferred alternative to conventional petroleum-based materials. With the global demand for eco-friendly products and stringent sustainability regulations, the market is gaining strong momentum across multiple industries. According to Prophecy Market Insights, the Bio-based Composite Material Market size was valued at USD 15.3
Power Purchase Agreement (PPA) Market Poised for Strong Growth Amid Rising Renewable Energy Adoption
Power Purchase Agreement (PPA) Market Poised for Strong Growth Amid Rising Renew …
Author: Shweta R., Business Development Specialist | Prophecy Market Insights Introduction The Power Purchase Agreement (PPA) Market is experiencing remarkable momentum, driven by the global transition toward renewable energy, carbon reduction targets, and rising demand for cost-effective electricity procurement models. PPAs-long-term contracts between electricity producers and buyers-are becoming a critical mechanism for corporations, utilities, and governments to achieve energy security, price stability, and sustainability commitments. With the accelerating deployment of solar, wind, and

All 4 Releases


More Releases for Phase

Three-Phase Hybrid Inverter Market Efficient and Reliable Power Conversion Solut …
Global Three-Phase Hybrid Inverter Market Overview: The Three-Phase Hybrid Inverter market is a broad category that includes a wide range of products and services related to various industries. This market comprises companies that operate in areas such as consumer goods, technology, healthcare, and finance, among others. In recent years, the Three-Phase Hybrid Inverter market has experienced significant growth, driven by factors such as increasing consumer demand, technological advancements, and globalization. This growth
Clinical Trials by Phase (Phase I, Phase II, Phase III, Phase IV) Market Forecas …
A clinical trial is a research study, where a group of people is given a test or treatment. Clinical trials study the safety and efficacy of tests and treatments. If the test or treatment is safe and meets regulatory requirements, then it is approved as a standard of care. Download Sample Copy at https://www.theinsightpartners.com/sample/TIPRE00006203/?utm_source=OpenPR&utm_medium=10379 Key Players Analysis:  IQVIA  Parexel International Corporation  Charles River Laboratories  ICON plc  SGS SA  Chiltern International Ltd  Syneos Health  PRA Health Sciences  Wuxi AppTec Inc  Pharmaceutical Product Development,
Digital Phase Shifters Market
Digital Phase Shifters Market A recently identified vacuum in the literature about the creation of digital phase shifters for modern communication systems is attempted to be filled in the book Design of Digital Phase Shifters for Multipurpose Communication Systems. By significantly reducing RF power consumption and improving noise immunity, directed beams enhance the development of new-generation mobile communication systems. In this regard, digital phase shifters in particular, which are part
COVID-19 - Pipeline Analysis 2020 for Global Market | Emphasis on Products cover …
COVID-19 (also known as Anderson COVID-19)?is a viral disease caused by RNA virus, SARS-CoV-2 or commonly known as corona virus. These viruses can cause respiratory, enteric, hepatic, and neurologic diseases. At the end of 2019, a new coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, China. It rapidly spread, resulting in an epidemic throughout China, followed by an increasing number of cases in other
Power Metering Market Information by type (smart, digital, analog), by phase (si …
Power Metering Market Information by type (smart, digital, analog), by phase (single phase, three phase) by application (residential, commercial and industrial) and Region - Forecast to 2022 The report for Global Power Metering Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and
HIV Vaccines Market Perceive Aggrandized Growth at a CAGR of 11.48% Till 2023 | …
HIV Vaccines Market Report Added on MarketResearchFuture.com with Overall Analysis. Key developments and Strategies Cover in this Report. The Market for Expected to Grow Globally Over the CAGR of 5 % During the Period 2018 to 2027 from USD 2,702.3 Billion in 2027. HIV Vaccines Market - Segmentation The global HIV vaccines market has been segmented on the basis of basis of antibiotics, type, and lastly, region. Antibiotics have been segmented into dicloxacillin,